%0 Journal Article
%A Allard, Pierre
%A Alhaj, Nareen
%A Lobitz, Stephan
%A Cario, Holger
%A Jarisch, Andreas
%A Grosse, Regine
%A Oevermann, Lena
%A Hakimeh, Dani
%A Tagliaferri, Laura
%A Kohne, Elisabeth
%A Kopp-Schneider, Annette
%A Kulozik, Andreas E
%A Kunz, Joachim B
%T Genetic modifiers of fetal hemoglobin affect the course of sickle cell disease in patients treated with hydroxyurea.
%J Haematologica
%V 107
%N 7
%@ 1592-8721
%C Pavia
%I Ferrata Storti Found
%M DKFZ-2021-02377
%P 1577-1588
%D 2022
%Z 2022 Jul 1;107(7):1577-1588
%X The course of sickle cell disease (SCD) is modified by polymorphisms boosting fetal hemoglobin (HbF) synthesis. However, it has remained an open question how these polymorphisms affect patients who are treated with the HbF-inducing drug hydroxyurea/hydroxycarbamide. The German SCD registry offers the opportunity to answer this question, because >90
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:34706496
%R 10.3324/haematol.2021.278952
%U https://inrepo02.dkfz.de/record/177243